Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREMI: First-line preventive treatment of migraine in primary care
2024-513597-22-00Phase 4Authorised
- Sponsor
- IDIAPJGol
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of amitriptyline, topiramate, flunarizine, propranolol and phentermine in migraine (5 arms), sponsored by IDIAPJGol. Primary endpoint: Primary endpoint: change in mean number of monthly migraine days at 12 weeks. Planned start Oct 2024; status: authorised.
02
Drugs
amitriptylinetopiramateflunarizinepropranololphentermine
03
Conditions
migraine
Beyond the preview
Go deeper on 2024-513597-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513597-22-00.